Front Row Advisors LLC Neurocrine Biosciences Inc Transaction History
Front Row Advisors LLC
- $282 Million
- Q2 2024
A detailed history of Front Row Advisors LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Front Row Advisors LLC holds 66 shares of NBIX stock, worth $7,384. This represents 0.0% of its overall portfolio holdings.
Number of Shares
66
Previous 76
13.16%
Holding current value
$7,384
Previous $10,000
10.0%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding NBIX
# of Institutions
641Shares Held
95.2MCall Options Held
661KPut Options Held
227K-
Black Rock Inc. New York, NY14.2MShares$1.59 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.13 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$516 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$276 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$264 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.7B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...